Enoxaparin v warfarin for secondary prophylaxis of venous thromboembolism in patients with cancer and venous thromboembolism ‡

Outcomes at 3 monthsEnoxaparinWarfarinRRR (95% CI)NNT (CI)
Treatment failure§10%21%51% (−10 to 78)Not significant
Major haemorrhage7%16%56% (−13 to 83)Not significant
Fatal haemorrhage0%8%100% (35 to 100)13 (7 to 38)
Mortality11%23%50% (−4.9 to 77)Not significant
‡Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article.
§Treatment failure = recurrent thromboembolism or major haemorrhage.
Cancer progression17%13%27% (−40 to 170)Not significant